Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
4.570
-2.160 (-32.10%)
At close: May 15, 2026, 4:00 PM EDT
4.520
-0.050 (-1.09%)
After-hours: May 15, 2026, 7:58 PM EDT

Aardvark Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-69.87-57.59-20.59-7.21-7.21
Depreciation & Amortization
0.040.040.02--
Stock-Based Compensation
5.723.950.440.310.31
Other Adjustments
-0.98-0.920.471.151.15
Changes in Accounts Payable
2.010.240.80.780.78
Changes in Accrued Expenses
3.756.421.39-0-0
Changes in Other Operating Activities
-2.32-6.3-0.61-0.86-0.86
Operating Cash Flow
-61.65-54.17-18.09-5.82-5.82
Capital Expenditures
-0.05-0.1-0.11--
Purchases of Investments
-4.95-129.6-11.89--
Proceeds from Sale of Investments
102.2580.03---
Investing Cash Flow
97.21-49.67-12--
Issuance of Common Stock
0.2691.640.33--
Net Common Stock Issued (Repurchased)
0.2691.640.33--
Issuance of Preferred Stock
--85--
Net Preferred Stock Issued (Repurchased)
--85--
Other Financing Activities
-0.08-2.39-3.34--
Financing Cash Flow
0.3889.2581.99--
Net Cash Flow
35.93-14.5951.91-5.82-5.82
Free Cash Flow
-61.7-54.27-18.2-5.82-5.82
Free Cash Flow Per Share
-2.84-2.77-4.55-1.47-1.50
Levered Free Cash Flow
-66.44-57.29-19.11-7.29-13.65
Unlevered Free Cash Flow
-71.29-62.43-21.31-7.5-11.44
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q